论文部分内容阅读
英夫利昔为新型的抗肿瘤坏死因子(TNF-α)药物,临床应用于治疗类风湿性关节炎、牛皮癣、银屑病关节炎、强直性脊柱炎和克罗恩病。药源性狼疮是英夫利昔少见的不良反应,但严重性不容忽视。本文将针对英夫利昔所致药源性狼疮发生率、发生时间、临床表现、危险因素、发生机制及处理原则进行阐述。
Infliximab is a novel anti-tumor necrosis factor (TNF-α) drug, which has clinical application in the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. Drug-induced lupus is a rare adverse reaction of infliximab, but the severity can not be ignored. This article will address the incidence of drug-induced lupus in infliximab, time of occurrence, clinical manifestations, risk factors, mechanism and treatment principles elaborated.